Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314895 | 0.86 | L3MBTL1 (0.56) | L3MBTL1PPARAALDH1A1LMNAHTT | |
| SCHEMBL18545548 | 0.86 | PDK2 (0.52) | L3MBTL1PDK2ALDH1A1LMNA | |
| SCHEMBL30417216 | 0.85 | L3MBTL1 (0.47) | L3MBTL1PPARAPDK2NPSR1HTR2C | |
| SCHEMBL2245966 | 0.85 | AKT1 (0.48) | L3MBTL1PDK2HTR2CSLC6A4CTSB | |
| SCHEMBL25829780 | 0.85 | L3MBTL1 (0.46) | L3MBTL1PDK2HTR2CSLC6A4CTSB | |
| SCHEMBL23420055 | 0.84 | L3MBTL1 (0.46) | L3MBTL1PDK2ALDH1A1LMNACTSB | |
| SCHEMBL7018101 | 0.84 | L3MBTL1 (0.46) | L3MBTL1PPARAPDK2ALDH1A1LMNA | |
| SCHEMBL7775544 | 0.84 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1HTR2CSLC6A4HDAC1 | |
| SCHEMBL6987866 | 0.83 | L3MBTL1 (0.59) | L3MBTL1PPARAALDH1A1LMNAHTT | |
| SCHEMBL8501723 | 0.83 | L3MBTL1 (0.59) | L3MBTL1PPARAALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMAC, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20230382923-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230159557-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-05-25 | — | — | US | disclosed |
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-06-07 | — | — | US | disclosed |
| EP-3298011-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-03-08 | — | — | US | disclosed |
| US-9815834-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9567334-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-3102577-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2016191172-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-07-14 | — | — | US | disclosed |
| WO-2015120049-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | L3MBTL1 4162/4885PPARA 271/4885PDK2 239/4885 |
| US-12162882-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | L3MBTL1 4748/4885PPARA 344/4885PDK2 381/4885 |
| US-11078199-B2 | Quinolone derivatives as fibroblast growth factor receptor inhibitors | FGFR1, FGFR3, FGFR2 | L3MBTL1 4748/4885PPARA 344/4885PDK2 381/4885 |
| US-20230159557-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, BRCA1 | L3MBTL1 1283/4885PPARA 3738/4885PDK2 1247/4885 |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | L3MBTL1 967/4885PPARA 798/4885PDK2 3406/4885 |
| US-20160200725-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | L3MBTL1 4748/4885PPARA 344/4885PDK2 381/4885 |
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | L3MBTL1 4584/4885PPARA 320/4885PDK2 307/4885 |
| US-11807649-B2 | Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2 | ERBB2, ERBB3, BRCA1 | L3MBTL1 1283/4885PPARA 3738/4885PDK2 1247/4885 |
| US-20240092777-A1 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | FGFR1, FGFR3, FGFR2 | L3MBTL1 4748/4885PPARA 344/4885PDK2 381/4885 |
| US-20230382923-A1 | FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, BRCA1 | L3MBTL1 1283/4885PPARA 3738/4885PDK2 1247/4885 |
| US-20160229849-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | L3MBTL1 4748/4885PPARA 344/4885PDK2 381/4885 |
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | L3MBTL1 4748/4885PPARA 344/4885PDK2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.